Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06820476
PHASE1

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The study is testing a new study medicine called NNC0487-0111 for weight control in Chinese people with Body mass index (BMI) greater than or equal to (\>=) 24 kilogram per square meter (kg/m\^2). The aim of this study is to find out how safe the study medicine is and how it behaves in your body. Participants will either get NNC0487-0111 or placebo. Which treatment participants will get is decided by chance. Oral NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. The study will last for about 60 days.

Official title: Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Oral Doses of NNC0487-0111 in Chinese Participants With Overweight or Obesity

Key Details

Gender

MALE

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

29

Start Date

2025-02-09

Completion Date

2025-05-14

Last Updated

2026-08-25

Healthy Volunteers

No

Interventions

DRUG

NNC0487-0111

Participants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.

DRUG

Placebo (NNC0487-0111)

Participants will be randomized to receive a placebo tablet orally matched to NNC0487-0111.

Locations (2)

Jinan Central Hospital

Ji'Nan, Shandong, China

Jinan Central Hospital

Jinan, Shandong, China